Adva Network Security launches strategic project within European collaboration to create sovereign clouds
Adva Network Security announced today that it is launching a nationally funded project to develop cloud-optimized, secure network access technology. As part of the Important Projects of Common European Interest (IPCEI), a comprehensive funding initiative is underway to create scalable, real-time and open Next-Generation Cloud Infrastructure and Services (IPCEI-CIS) aimed at ensuring digital sovereignty. Among the 19 German companies participating, Adva Network Security is responsible for developing highly secure network access technology featuring an integrated edge cloud and software solution for robust operation. The solution will be an essential component of a European independent cloud platform, enabling the rapid processing of mission-critical and sensitive data at the network edge.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320831952/en/
Funded by the European Union – NextGenerationEU (Graphic: Business Wire)
“The security of mission-critical networks poses major challenges for operators: Quantum computing threatens to compromise established security mechanisms, while the push for digitization requires fast and trusted data processing at the edge of networks. Our project within IPCEI-CIS addresses both of these problems and offers very simple operation through automation,” said Wolfgang Keil, senior director of cybersecurity project management at Adva Network Security. “Leveraging our experience in quantum security, protected hosting and the operation of high-security networks, we’re developing highly secure access to the European cloud. This includes protected hosting of virtualized network functions at the edge, enabling sensitive data to be processed safely and quickly on-site before being transferred securely to the cloud.”
The TRUsted cloud connectivity for automated Endpoint SECurity (TRUE-SEC) project was launched on January 1, 2024, and will run for three years. It is funded by the Federal Ministry for Economic Affairs and Climate Protection based on a resolution of the German Bundestag and financed by the European Union. Its mission is to create an innovative solution for secure network access. Renowned for its expertise in the high-security network domain, Adva Network Security has been entrusted with developing this critical component for an end-to-end European cloud infrastructure. In collaboration with many project partners, IPCEI-CIS aims to establish a standardized, open and sustainable cloud infrastructure that ensures future-proof security for data services that are compliant with stringent regulatory requirements. The initiative marks a crucial step in advancing autonomous and sovereign cloud technology across Europe.
“Already deployed across numerous high-security networks, our technology safeguards some of the most sensitive and mission-critical data. Yet, new threat scenarios require continuous improvement. Through our participation in the IPCEI-CIS initiative, we’re making an important contribution to the sovereignty of European cloud infrastructure and services,” commented Michael Roth, GM of Adva Network Security. “The funding will enable us to expand our competence center for network security in Berlin. Our growing team of cybersecurity and network specialists is playing a vital role in driving the security – and thereby the acceptance – of cloud services through innovative and technologically sophisticated solutions. We’re proud to be able to make this contribution and honored to help shape Germany’s digital future.”
About Adva Network Security
Adva Network Security has built a fierce reputation for protecting packet optical networks. We pioneered low-latency, multi-layer encryption solutions that are right now safeguarding data in motion for many mission-critical applications. Our ConnectGuard™ security technology is even combating tomorrow’s quantum security threats. Built by the industry’s leading security experts, our German-based organization helps organizations and government agencies security-harden their networks to ensure critical infrastructure is protected against cyber threats. Our development and manufacturing processes, as well as our security solutions, have been approved and certified by leading governmental security agencies. For more information on how we can help you, please visit www.advasecurity.com.
Published by
Adva Network Security GmbH, Berlin, Germany
www.advasecurity.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240320831952/en/
Contact information
For media
Ulrich Kohn
t +49 30 2636969166
info@advasecurity.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AdvanCell to participate in Jefferies Global Healthcare Conference in London11.11.2025 15:00:00 EET | Press release
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, will attend theJefferies Global Healthcare ConferenceinLondon from 17 to 20 November 2025. The AdvanCell team – Andrew Adamovich (CEO),Anna Karmann (CMO), Matthew Vincent (CBO), Simon Puttick (CSO) and Dayle Hogg (COO) - will discuss the company’s clinical and corporate progress, including the encouraging Phase 1b trial results for 212Pb-ADVC001, recently presented at ESMO, as well as the upcoming Phase 2 expansion in metastatic castration-resistant (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and progress on the company’s US expansion. “It’s an incredibly exciting time for AdvanCell,” said Andrew Adamovich, CEO of AdvanCell. “We are very encouraged by the promising Phase 1 data for ADVC001. We are expanding our US operations and manufacturing capabilities to support the next stage of development for our company, our lead asset and our pipeline. We loo
The Future Is Set for Tourism’s Next Era as the Inaugural TOURISE Summit Opens11.11.2025 14:51:00 EET | Press release
With the bold ambition to rewrite the rules of travel, the inaugural TOURISE Summit under the patronage of His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister was officially opened today by H.E. Ahmed Al Khateeb, Minister of Tourism of Saudi Arabia and Chairman of TOURISE. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111716065/en/ His Excellency Ahmed Al Khateeb, Saudi Arabia's Minister of Tourism and Chairman of TOURISE, opens the inaugural TOURISE Summit in Riyadh. TOURISE ushers in a new era for global tourism, uniting ministers, delegates, and visionaries from around the world as the premier platform dedicated to shaping the future of global tourism. Taking place from November 11-13, 2025, immediately following the 50th United Nations Tourism General Assembly, TOURISE is reimagining the way that sectors interact to find opportunities where competitors become partners
Riyadh Declaration on the Future of Tourism Sets 50-Year Roadmap as UN Tourism 26th General Assembly Closes in Saudi Arabia11.11.2025 14:39:00 EET | Press release
The 26th session of the UN Tourism General Assembly concluded today with the adoption of the Riyadh Declaration on the Future of Tourism, a momentous step taken by member states toward enhanced cooperation over the next 50 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111034542/en/ 26th UN Tourism General Assembly The Declaration reaffirms the Kingdom’s leadership in global tourism and its position at the heart of major, industry-changing decisions, as the ground-breaking Declaration is poised to play a central role in advancing the 2030 Agenda for Sustainable Development, emphasizing sustainability, digital innovation, AI integration, and inclusive tourism economies. The Riyadh Declaration on the Future of Tourism is a shared roadmap to guide the sector’s next half-century around sustainability, inclusion and AI-powered innovation.It underscores strengthening international cooperation, resilience, and the empower
Prokarium Appoints Ibs Mahmood as Chief Executive Officer11.11.2025 14:06:00 EET | Press release
Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the appointment of Ibs Mahmood as Chief Executive Officer (CEO). Ibs succeeds Kristen Albright, who will join the Board of Directors to continue shaping Prokarium’s strategic direction. Ibs brings 25 years as a biotechnology entrepreneur having founded and led multiple life science companies through clinical development, financing and strategic transactions, raising more than $300 million for his own ventures and over $2 billion for clients. He previously co-founded and led AMO Pharma, DrugDev and Induction Healthcare, and enjoyed senior roles at IQVIA, Abingworth, Shire Pharma and Investec. Ibs read medicine at the University of Oxford. “Ibs’ appointment marks an important step in Prokarium’s evolution. His unique blend of medical insight, entrepreneurial drive and industry experience will help us accelerate our mission to change the treatment paradigm in bladder canc
FDA Approves Promega OncoMate ® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA ® in Combination with LENVIMA ® In Advanced Endometrial Carcinoma11.11.2025 14:00:00 EET | Press release
The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate® MSI Dx Analysis System as a companion diagnostic designed to identify patients with microsatellite stable (MSS; defined as not MSI-high [not MSI-H]) endometrial carcinoma who may benefit from treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai. This is the first Promega companion diagnostic to receive FDA approval. OncoMate® MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue. MSI status can be used to guide treatment decisions and support precision oncology strategies in endometrial carcinoma. “This approval underscores the critical role diagnostics play in accurately matching the right patients, at the right time with the right therapy,” says Alok Sharma, Global Clinical Market Director at Promega. “We are committed to delivering reliable
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
